Susan Cohn to Prospective Studies
This is a "connection" page, showing publications Susan Cohn has written about Prospective Studies.
Connection Strength
0.391
-
Efficacy of post-induction therapy for high-risk neuroblastoma patients with end-induction residual disease. Cancer. 2022 08 01; 128(15):2967-2977.
Score: 0.100
-
Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531. J Clin Oncol. 2019 12 01; 37(34):3243-3255.
Score: 0.082
-
Outcomes of patients with intermediate-risk neuroblastoma presenting with motor deficits relating to intraspinal tumor extension: A report from the Children's Oncology Group study ANBL0531. Pediatr Blood Cancer. 2025 Jan; 72(1):e31407.
Score: 0.030
-
Evaluation of Image-Defined Risk Factor (IDRF) Assessment in Patients With Intermediate-risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531. J Pediatr Surg. 2025 Jan; 60(1):161896.
Score: 0.029
-
Factors influencing parents' choice of palliative treatment goals for children with relapsed or refractory neuroblastoma: A multi-site longitudinal survey study. Cancer. 2024 04 01; 130(7):1101-1111.
Score: 0.028
-
Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium. J Clin Oncol. 2021 11 01; 39(31):3506-3514.
Score: 0.024
-
Racial and Ethnic Differences in Communication and Care for Children With Advanced Cancer. J Pain Symptom Manage. 2020 10; 60(4):782-789.
Score: 0.022
-
Unrealistic parental expectations for cure in poor-prognosis childhood cancer. Cancer. 2020 01 15; 126(2):416-424.
Score: 0.021
-
A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children's Oncology Group study. Ann Surg. 2012 Oct; 256(4):573-80.
Score: 0.013
-
Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children's Oncology Group study P9641. J Clin Oncol. 2012 May 20; 30(15):1842-8.
Score: 0.012
-
ABCC multidrug transporters in childhood neuroblastoma: clinical and biological effects independent of cytotoxic drug efflux. J Natl Cancer Inst. 2011 Aug 17; 103(16):1236-51.
Score: 0.012
-
Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. N Engl J Med. 2010 Sep 30; 363(14):1313-23.
Score: 0.011
-
Long-term follow-up of HIV-infected individuals who have significant increases in CD4+ cell counts during antiretroviral therapy. Clin Infect Dis. 2004 Nov 15; 39(10):1500-6.
Score: 0.007